GLP-1 Drugs Reduce Brain Aneurysm Rupture Risk by 34% in Diabetic Patients | Research

The takeaway

GLP-1 receptor agonist use was associated with 34% lower risk of subarachnoid hemorrhage and 37% lower mortality in diabetic patients with brain aneurysms over 5 years.

34% lower rupture risk
Diabetic patients with brain aneurysms on GLP-1 drugs had significantly lower risk of subarachnoid hemorrhage

What the researchers found

GLP-1RA use associated with lower SAH risk (HR 0.66, 95% CI 0.50-0.87) and mortality (HR 0.63, 95% CI 0.52-0.76) in matched diabetic patients with intracranial aneurysms over 5 years, confirmed in untreated aneurysm subgroup.

Why it matters

Brain aneurysm management is limited to surgery or observation. A medication that reduces rupture risk could save lives, especially in patients too sick for surgery.

How the study worked

Retrospective propensity-matched cohort study using TriNetX global database (2010-2025), matching on 95 variables including smoking and hypertension, with 5-year follow-up and falsification analysis.

What this study cannot tell us

Retrospective observational design. Only diabetic patients studied. Cannot determine mechanism. GLP-1 users may have better overall health management.

How to read the evidence

Large propensity-matched cohort with 95-variable matching and falsification analysis. Strong observational evidence but needs prospective confirmation.

When this study was published

Published in 2025.

The bigger picture

This is one of the first studies suggesting GLP-1 drugs could prevent cerebrovascular catastrophe, extending their vascular protective effects to the intracranial vasculature.

Questions still open

What mechanism explains GLP-1 drugs' protection against aneurysm rupture?
Should GLP-1 drugs be considered for non-diabetic patients with brain aneurysms?
Could GLP-1 therapy change the management algorithm for unruptured brain aneurysms?

Common questions

Can GLP-1 drugs prevent brain aneurysm rupture?

This large study suggests yes — diabetic patients on GLP-1 drugs had 34% lower risk of brain aneurysm rupture. The anti-inflammatory and blood pressure-lowering effects of these drugs may help protect aneurysm walls.

Should brain aneurysm patients take GLP-1 drugs?

This is early evidence. If you have diabetes and a known brain aneurysm, these findings support continuing GLP-1 therapy. Non-diabetic patients with aneurysms need separate study before recommendations can be made.

Read the original research

Glucagon-Like Peptide-1 Receptor Agonists and Decreased Subarachnoid Hemorrhage Risk in Patients With Intracranial Aneurysm.

Stroke, 57(3), 802-807

View on PubMed ↗Publisher’s paper ↗

Citation

Feghali, James; Ruchika, Fnu; Horowitz, Melanie A; Xu, Risheng; Jackson, Christopher M; Caplan, Justin M; Huang, Judy; Tamargo, Rafael J; Gonzalez, L Fernando. (2026). Glucagon-Like Peptide-1 Receptor Agonists and Decreased Subarachnoid Hemorrhage Risk in Patients With Intracranial Aneurysm.. Stroke, 57(3), 802-807. https://doi.org/10.1161/STROKEAHA.125.053599